Scholars@Duke

Optimizing Therapy to Match the Risk: Neoadjuvant Approaches to Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Publication ,  Journal Article
Thomas, A; Broderick, A; Anders, CK
Published in: JCO Oncol Pract
August 2024
Published version (DOI) Link to item

Duke Scholars

Alexandra Thomas
Author Alexandra Thomas Medicine, Medical Oncology

Published In

JCO Oncol Pract

DOI

10.1200/OP.24.00380

EISSN

2688-1535

Publication Date

August 2024

Volume

20

Issue

8

Start / End Page

1003 / 1005

Location

United States

Related Subject Headings

  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Neoadjuvant Therapy
  • Humans
  • Female
  • Breast Neoplasms
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Thomas, A., Broderick, A., & Anders, C. K. (2024). Optimizing Therapy to Match the Risk: Neoadjuvant Approaches to Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. JCO Oncol Pract, 20(8), 1003–1005. https://doi.org/10.1200/OP.24.00380
Thomas, Alexandra, Amanda Broderick, and Carey K. Anders. “Optimizing Therapy to Match the Risk: Neoadjuvant Approaches to Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.” JCO Oncol Pract 20, no. 8 (August 2024): 1003–5. https://doi.org/10.1200/OP.24.00380.
Thomas, Alexandra, et al. “Optimizing Therapy to Match the Risk: Neoadjuvant Approaches to Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.” JCO Oncol Pract, vol. 20, no. 8, Aug. 2024, pp. 1003–05. Pubmed, doi:10.1200/OP.24.00380.

Published In

JCO Oncol Pract

DOI

10.1200/OP.24.00380

EISSN

2688-1535

Publication Date

August 2024

Volume

20

Issue

8

Start / End Page

1003 / 1005

Location

United States

Related Subject Headings

  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Neoadjuvant Therapy
  • Humans
  • Female
  • Breast Neoplasms
  • 3211 Oncology and carcinogenesis